Wall Street Journal - Thomas Gryta - Jan 20, 2010
In 2008, Sandoz, the generic unit of Novartis AG (NVS, NOVN.VX), recalled generic Toprol XL after the FDA sent a warning letter about a manufacturing ...
Wall Street Journal - Sten Stovall - Jan 28, 2010
AstraZeneca said its latest results also benefited from a revival in sales of high-blood pressure drug Toprol-XL after generic competitors withdrew from the ...
Just take a look at Toprol XL, the AstraZeneca blood pressure treatment. In 2008, Novartis' generics unit Sandoz recalled its version on manufacturing ...
The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from the withdrawal of a generic, US sales of H1N1 vaccine and ...
It said the outlook for the rest of 2009 has been boosted by the withdrawal of generic products for Toprol-XL, additional orders for the H1N1 influenza ...
The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from the withdrawal of a generic, US sales of H1N1 vaccine and ...
... flu and Toprol-XL revenues, which more than doubled to $1.12bn in the first nine months of last year because of the withdrawal of two generic rivals. ...
... cleverly maintained earnings despite challenges from companies that make generic drugs and it even got a boost last year from strong sales of Toprol-XL, ...
Email this story